Join Growin Stock Community!

Medtronic plcMDT.US Overview

US StockHealthcare
(No presentation for MDT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MDT AI Insights

MDT Overall Performance

MDT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MDT Recent Performance

-1.96%

Medtronic plc

-3.61%

Avg of Sector

-2.16%

S&P500

MDT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MDT Key Information

MDT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MDT Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Price of MDT

MDT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MDT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.59
PE Ratio (TTM)
27.28
Forward PE
15.69
PS Ratio (TTM)
3.53
PB Ratio
2.56
Price-to-FCF
22.95
METRIC
VALUE
vs. INDUSTRY
Gross Margin
64.86%
Net Margin
13.00%
Revenue Growth (YoY)
6.88%
Profit Growth (YoY)
6.20%
3-Year Revenue Growth
5.28%
3-Year Profit Growth
4.54%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.59
PE Ratio (TTM)
27.28
Forward PE
15.69
PS Ratio (TTM)
3.53
PB Ratio
2.56
Price-to-FCF
22.95
Gross Margin
64.86%
Net Margin
13.00%
Revenue Growth (YoY)
6.88%
Profit Growth (YoY)
6.20%
3-Year Revenue Growth
5.28%
3-Year Profit Growth
4.54%

  • When is MDT's latest earnings report released?

    The most recent financial report for Medtronic plc (MDT) covers the period of 2026Q3 and was published on 2026/01/23. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MDT's short-term business performance and financial health. For the latest updates on MDT's earnings releases, visit this page regularly.

  • Where does MDT fall in the P/E River chart?

    According to historical valuation range analysis, Medtronic plc (MDT)'s current price-to-earnings (P/E) ratio is 26.93, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of MDT?

    According to the latest financial report, Medtronic plc (MDT) reported an Operating Profit of 1.46B with an Operating Margin of 16.22% this period, representing a decline of 11.06% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is MDT's revenue growth?

    In the latest financial report, Medtronic plc (MDT) announced revenue of 9.02B, with a Year-Over-Year growth rate of 8.74%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does MDT have?

    As of the end of the reporting period, Medtronic plc (MDT) had total debt of 28.07B, with a debt ratio of 0.31. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does MDT have?

    At the end of the period, Medtronic plc (MDT) held Total Cash and Cash Equivalents of 1.15B, accounting for 0.01 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does MDT go with three margins increasing?

    In the latest report, Medtronic plc (MDT) achieved the “three margins increasing” benchmark, with a gross margin of 63.8%%, operating margin of 16.22%%, and net margin of 12.7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess MDT's profit trajectory and future growth potential.

  • Is MDT's EPS continuing to grow?

    According to the past four quarterly reports, Medtronic plc (MDT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.89. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MDT?

    Medtronic plc (MDT)'s Free Cash Flow (FCF) for the period is 2.3B, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 9.73% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.